Montelukast Fair-Med

Montelukast, the active ingredient in Montelukast Fair-Med, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children, and is approved for maintenance therapy in the European Union.

GNH USA supplies Montelukast Fair-Med as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. We provide consistent quality, regulatory documentation, and reliable logistics to meet the needs of healthcare providers across multiple regions.

Montelukast acts on the leukotriene pathway and is indicated for several respiratory and allergic conditions, providing anti‑inflammatory benefits. - Asthma (maintenance therapy): reduces frequency of asthma attacks, improves lung function, and helps control symptoms in both adults and children. - Allergic rhinitis: relieves nasal congestion, sneezing, itching, and rhinorrhea associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways that occurs during or after physical activity, enhancing exercise tolerance.

Montelukast is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate head pain that may occur shortly after starting therapy. - Abdominal pain: discomfort or cramping in the stomach area, often transient. - Cough: dry or productive cough that can appear during treatment. - Nausea: feeling of queasiness or urge to vomit that may be mild or moderate. - Dizziness: sensation of light‑headedness or unsteadiness that can occur, especially when standing quickly.

Serious or Rare Side Effects: - Angioedema: rapid swelling of the face, lips, tongue or throat that may compromise breathing. - Anaphylaxis: severe, potentially life‑threatening allergic reaction with hives, difficulty breathing, and hypotension. - Mood changes: emergence of depression, anxiety, or suicidal thoughts requiring immediate medical attention. - Stevens‑Johnson syndrome: rare, severe skin reaction characterized by blistering and detachment of the epidermis, requiring urgent care. - Other rare reactions: severe hepatic injury or eosinophilic granulomatosis with polyangiitis have been reported in isolated cases.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: safety not established; use only if potential benefit justifies potential risk. - Breastfeeding: unknown excretion in milk; weigh benefits against possible infant exposure. - Liver impairment: use with caution; monitor hepatic function as metabolism occurs hepatically. - Concomitant CYP3A4 inducers: drugs such as phenobarbital or rifampin may lower montelukast levels, reducing efficacy. - Renal impairment: no routine dose adjustment is needed, but monitor patients with severe renal dysfunction. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Phenobarbital: strong enzyme inducer that can markedly reduce montelukast plasma concentrations, decreasing efficacy. - Rifampin: potent CYP3A4 inducer that lowers drug exposure and may compromise asthma control. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase montelukast levels, raising risk of adverse effects. - Carbamazepine: enzyme inducer that may reduce montelukast levels.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may modestly raise montelukast concentrations. - Erythromycin: may slightly increase exposure; monitor for headache or gastrointestinal upset. - Warfarin: potential for increased anticoagulant effect; monitor INR closely.